Policy As for the third part of the triad between obesity and CVD a contributory role has been well established, with mounting data now indicating that excess body weights association with CVD risk seems to be independent of its promotion of individual risk factors such as hypertension
10.1021/bi0014498 84 XueL
There are side effects that may occur from GLP-1 medications, including possible serious risks if dosages are not correctly administered, but most side effects include dehydration and stomach issues, like nausea, diarrhea or constipation
Clinical trials (SURPASS for type 2 diabetes and SURMOUNT for obesity) have demonstrated substantial weight reduction in people taking tirzepatide, with weight loss varying by indication, dose, and population
31,32 Accordingly, a meta-analysis including 68,653 patients from 10 trials showed that GLP-1 RAs reduce HF hospitalisations only in patients without history of previously diagnosed HF
Note the trial has no numbered "TRIUMPH-n" acronym its registered name is TRIUMPH-Outcomes